At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 617 enrolled
Drug / intervention
Low Dose Asenapine maleate transdermal patch +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, 6-Week, In-Patient Study to Assess Efficacy and Safety of HP-3070 in Subjects Diagnosed With Schizophrenia
In Brief
A Phase 3 clinical trial evaluating Low Dose Asenapine maleate transdermal patch, High Dose Asenapine maleate transdermal patch, and 1 other intervention for Schizophrenia. Completed, enrolled 617 participants across 1 site.
Detailed Summary
This study is designed to evaluate efficacy and safety of HP-3070 compared with placebo transdermal patch in subjects diagnosed with schizophrenia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartAug 2016
First PostedAug 2016
Primary CompletionJun 2018
TodayJul 2026
First PostedAug 24, 2016
Enrollment StartAug 1, 2016
Primary CompletionJun 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 9.9 years ago
Interventions
Low Dose Asenapine maleate transdermal patchdrug
The study will evaluate low dose Asenapine maleate transdermal patch
High Dose Asenapine maleate transdermal patchdrug
The study will evaluate high dose Asenapine maleate transdermal patch
Placebodrug
The study will evaluate placebo transdermal patch.